Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + Etrumadenant + Zimberelimab in MTAP-Deficient Urothelial Carcinoma
NCT05335941Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of etrumadenant, zimberelimab in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2023; status: active, not recruiting.
02
Drugs
etrumadenantzimberelimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05335941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335941.